Skip to Main Content

Author Details

Yong-Jie Lu
Barts Cancer Institute, Queen Mary University of London
1993
127
40
PMIDPaper TitleJournal TitlePublished Year
36394342Hsa_circ_0094606 promotes malignant progression of prostate cancer by inducing M2 polarization of macrophages through PRMT1-mediated arginine methylation of ILF3.Carcinogenesis2023
37353740Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1).BMC Cancer2023
37292833Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry.medRxiv2023
37311464Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.Am J Hum Genet2023
37268719Circulating tumour cells for early detection of clinically relevant cancer.Nat Rev Clin Oncol2023
36727071The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.Front Oncol2023
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
35530277The interaction of <i>p53</i> and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies.Am J Cancer Res2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
33473200Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33490068The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing.Front Cell Dev Biol2021
33623038Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nat Commun2021
34540821A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer.Front Cell Dev Biol2021
33398198Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33477882The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis.Cancers (Basel)2021
31580196Reply by Authors.J Urol2020
31389764Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.J Urol2020
30622367Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2019
31482460Fluorescence In Situ Hybridization and Rehybridization Using Bacterial Artificial Chromosome Probes.Methods Mol Biol2019
31482451The Isolation and Analysis of Circulating Tumor Cells.Methods Mol Biol2019
31218098The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors.Am J Cancer Res2019
31102277Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.J Pathol2019
29662167Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet2018
29892050Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nat Commun2018
29892016Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2018
29878078AA9int: SNP interaction pattern search using non-hierarchical additive model set.Bioinformatics2018
29902261PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.PLoS One2018
30031830The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.Urology2018
30397198Germline variation at 8q24 and prostate cancer risk in men of European ancestry.Nat Commun2018
29362360Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Adâ¿¿â¿¿ through Bcl-2-dependent attenuation of autophagy.Oncogenesis2018
29662627Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway.Oncotarget2018
27960240Postchemotherapy changes in testicular germ cell tumours: biology and morphology.Histopathology2017
28945760Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.PLoS Genet2017
28698647Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.Sci Rep2017
28615267The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.Clin Cancer Res2017
28039167SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns.Bioinformatics2017
26881390A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population.Oncotarget2016
27648364Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Am J Cancer Res2016
27588475NKAIN2 functions as a novel tumor suppressor in prostate cancer.Oncotarget2016
27815922Erratum to: TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.Tumour Biol2016
27329728MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.Oncotarget2016
27320318TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.Tumour Biol2016
25281662DNA replication-dependent induction of gene proximity by androgen.Hum Mol Genet2015
26628996High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.Int J Clin Exp Med2015
26397728Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.PLoS One2015
26770299The structure and function of NKAIN2-a candidate tumor suppressor.Int J Clin Exp Med2015
26126881Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies.Med Sci Monit2015
26175942AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation.Am J Cancer Res2015
26112306Protein S-palmitoylation and cancer.Biochim Biophys Acta2015
25837820Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.Cancer Epidemiol Biomarkers Prev2015
  • 1 - 50 of 127

Recommended Authors

Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 3
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 7
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2002
Number of shared co-authors 7
Maryou B Lambros
The Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 10
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 1
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 3
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 8
Anna Lapuk
Contextual Genomics Inc.
Career Start Year 1998
Number of shared co-authors 5
Danny Wangsa
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 0
Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1996
Number of shared co-authors 9
Alexei Protopopov
The University of MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 10
Yi-Mi Wu
University of Michigan Medical School ann arbor
Career Start Year 1995
Number of shared co-authors 8
Jane Bayani
Ontario Institute for Cancer Research
Career Start Year 1995
Number of shared co-authors 3
Volker Jung
Clinic of Urology and Pediatric Urology, University of Saarland
Career Start Year 1994
Number of shared co-authors 0
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 27
Holger S??ltmann
German Cancer Research Center (DKFZ)
Career Start Year 1993
Number of shared co-authors 8
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Career Start Year 1992
Number of shared co-authors 7
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 43
Nallasivam Palanisamy
Vattikuti Urology Institute
Career Start Year 1990
Number of shared co-authors 6
Thomas Ried
Center for Cancer Research, National Cancer Institute
Career Start Year 1989
Number of shared co-authors 5
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 16
Jonathan R Pollack
Stanford University School of Medicine
Career Start Year 1987
Number of shared co-authors 1
Peter Lichter
German Cancer Research Center (DKFZ)
Career Start Year 1986
Number of shared co-authors 17
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 23
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 2
Jeremy A Squire
University of Sao Paulo
Career Start Year 1982
Number of shared co-authors 13
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 1
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 34
Francesca Demichelis
University of Trento
Career Start Year 1969
Number of shared co-authors 19

Collaborators

Daniel M Berney
Barts Cancer Institute, Queen Mary University of London
Co-authored papers 35
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 21
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 19
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 19
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 16
Douglas F Easton
University of Cambridge
Co-authored papers 16
Johanna Schleutker
Institute of Biomedicine, University of Turku
Co-authored papers 16
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 15
Stephen N Thibodeau
Mayo Clinic
Co-authored papers 15
Børge G Nordestgaard
Co-authored papers 15
Christopher A Haiman
University of Southern California
Co-authored papers 15
Sue A Ingles
Co-authored papers 14
Fredrik Wiklund
Co-authored papers 14
Ruth C Travis
Co-authored papers 14
Freddie C Hamdy
University of Oxford
Co-authored papers 14
Henrik Gr??nberg
Karolinska Institute
Co-authored papers 14
Graham G Giles
Co-authored papers 13
Colin S Cooper
Norwich Medical School, University of East Anglia
Co-authored papers 13
Judith A Clements
Co-authored papers 12
Sonja I Berndt
Co-authored papers 12
Tokhir Dadaev
The Institute of Cancer Research
Co-authored papers 12
Esther M John
Co-authored papers 12
Demetrius Albanes
Co-authored papers 12
Kay-Tee Khaw
Co-authored papers 11
Daniel J Schaid
Mayo Clinic
Co-authored papers 11
Kathryn L Penney
Co-authored papers 10
Lorelei A Mucci
Co-authored papers 10
Loic Le Marchand
Co-authored papers 10
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 10
Catharine M L West
University of Manchester
Co-authored papers 10
Release 1.2